Atai Life Sciences N.V. (ATAI)
After hours:
| Previous Close | 4.0400 |
| Open | 4.1500 |
| Bid | 3.8900 x 900 |
| Ask | 4.2500 x 1300 |
| Day's Range | 3.9800 - 4.2200 |
| 52 Week Range | 3.0500 - 22.9100 |
| Volume | |
| Avg. Volume | 848,575 |
| Market Cap | 662.22M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2140 |
| Earnings Date | May 16, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.31 |
- GlobeNewswire
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usability study in patients and COMPASS’ end of Phase 2 FDA meeting – Ended the first quarter with $335 million cash, maintaining atai’s position as a well-funded, leading mental health company Video int
- GlobeNewswire
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (Nasdaq: ATAI), please note the first and second paragraphs, which contained statements referencing the 2022 IR financial results posting and executives on the video interview, as well as forward-looking statements, have been modified. The corrected release follows: atai Life Sciences N.V. (Nasdaq: ATAI) (“ata
- GlobeNewswire
atai Life Sciences to Announce First-Quarter 2022 Financial Results
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR portion of its website. Please visit the atai investor relations website at https://ir.atai.life to view Q1’22 financial results and press release. A video interview with atai Life Sciences CEO Florian Brand, CSO Srinivas
